Stocktoria

Larimar Therapeutics, Inc. LRMR

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-06-19

Larimar Therapeutics, Inc. statistics & valuation

Market cap$380.2M
P / B4.9×
Return on capital-212.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
2016201720182019202020212022202320242025
Return on equity (%)
-47.50% -66.50% -2106.00% -47.40% -78.60% -31.90% -45.20% -46.90% -212.20% 2016201720182019202020212022202320242025
Shares outstanding
27.3M 27.5M 37.3M 6.1M 15.4M 17.7M 43.3M 43.9M 63.8M 83.1M 2016201720182019202020212022202320242025
Net debt ($)
-$29.2M -$20.8M -$29.3M $13.5M 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-44.00% -49.30% -50.40% -444.80% -40.60% -64.40% -28.00% -38.50% -40.30% -113.60% 2016201720182019202020212022202320242025
Free cash flow margin (%)
2016201720182019202020212022202320242025
Debt / equity (×)
0.03× 0.26× 6.86× 2016201720182019202020212022202320242025
EPS ($)
-$3.57 -$2.95 -$1.37 -$0.84 -$1.32 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Return on assets-113.6%-40.3%-38.5%-28.0%-64.4%-40.6%-444.8%-50.4%-49.3%-44.0%
Return on equity-212.2%-46.9%-45.2%-31.9%-78.6%-47.4%3333.1%-2106.0%-66.5%-47.5%
Debt / equity——————-20.96×6.86×0.26×0.03×
Current ratio2.198.029.4911.288.1610.890.819.1214.3913.23

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.